Amplia Therapeutics Ltd has released a press release.
Proposed issue of Securities - ATX
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Announces $3.8m Share Placement
- Preclinical Data Support Developmnt AMP945 Pancreatic Cancer
- Quarterly Report and Shareholder Update
- ATX FAK Inhibitors Reduce Fibrosis in Animal Model of NASH
- Amplia Completes Dosing in Phase 1 Clinical Study of AMP945
Later from Amplia Therapeutics
- App 4E - Preliminary Final Report YE 31 March 2021
- AMP945 Improves Survival in Pacnreatic Cancer Model
- Amplia and Garvan Enter Into Collaboration Agreement
- Results from Successful Phase 1 Clinical Trial of AMP945
- Quarterly Activities and Cashflow Reports and Presentation
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics